Acceleron Archives -

Activist investors are pushing back against Merck & Co’s recent $11.5 billion deal to acquire Acceleron Pharma, arguing

Acceleron investors dig their heels in on Merck takeover bid

https://pharmaphorum.com/news/acceleron-investors-dig-their-heels-in-on-merck-takeover-bid/

After days of speculation, Merck & Co confirmed today that it has agreed to acquire Acceleron Pharma $1.5

Merck confirms $11.5bn Acceleron takeover deal

https://pharmaphorum.com/news/merck-confirms-11-5bn-acceleron-takeover-deal/

US biopharma company Acceleron is the next company heading for a takeover by a big pharma group –

Rumour mill says Acceleron is speeding towards $11bn sale

https://pharmaphorum.com/news/rumour-mill-says-acceleron-is-speeding-towards-11bn-sale/

Bristol-Myers Squibb has taken another step towards achieving its blockbuster hopes for beta thalassaemia-associated anaemia therapy Reblozyl, after

EHA21: Study raises BMS’ hopes for Reblozyl in less severe disease

https://pharmaphorum.com/news/eha21-study-raises-bms-hopes-for-reblozyl-in-less-severe-patients/

Bristol-Myers Squibb has moved a step closer to EMA approval of Reblozyl, a therapy for anaemia that has

CHMP backs BMS’ first-in-class anaemia drug Reblozyl

https://pharmaphorum.com/news/chmp-backs-bms-first-in-class-anaemia-drug-reblozyl/

The FDA has approved Celgene and Acceleron’s Reblozyl, which is the first drug to be approved in the

Celgene scores FDA okay for thalassaemia drug Reblozyl

https://pharmaphorum.com/news/celgene-scores-fda-okay-for-thalassaemia-drug-reblozyl/

Acceleron has axed clinical development of its ACE-083 in the inherited muscle-wasting disease muscular dystrophy, after the drug

Acceleron axes clinical development of muscular dystrophy drug

https://pharmaphorum.com/news/acceleron-axes-clinical-development-of-muscular-dystrophy-drug/

Acceleron